



## **Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022**

### **MVdeltaC shows encouraging results in several preclinical models of solid tumors such as mesothelioma, bladder cancer and neuroblastoma**

**Paris, France, November 2, 2022** - Oncovita, a French biotech company specialized in therapeutic and prophylactic vaccines, today announces that the main preclinical data on MVdeltaC, its first therapeutic vaccine candidate targeting solid tumors, will be presented at the [Society for Immunotherapy of Cancer 37th Annual Meeting \(SITC 2022\)](#), to be held in Boston, M.A. (USA) on November 8-12, 2022.

The company will present the latest developments in its first oncolytic vaccine candidate. MVdeltaC is based on the Measovir™ proprietary technology, derived from safe and highly immunogenic measles attenuated vaccine virus, which has been used successfully for the development of several prophylactic vaccines.

Oncovita's chief scientific officer Frédéric Tangy, PhD, and CEO, Jean-François Le Bigot, PhD, will present a poster, #1315, titled 'MVdeltaC, a new therapeutic vaccine demonstrates promising preclinical immuno-oncolytic activities,' on Thursday, November 10 during the post-hall session C from 9am to 9pm EST.

This presentation will include results obtained from *in vitro* and *in vivo* models of solid tumor experiments, including PDX models and syngeneic models in immunocompetent mice, such as mesothelioma, bladder cancer and neuroblastoma. MVdeltaC exhibits a very strong immunogenic apoptotic activity resulting in tumor regression and up to a total disappearance of the tumors in immunocompetent models. In addition, when animals which completely rejected the tumor were re-challenged with tumor cells, no tumor growth was observed, suggesting an immune protection.

"We look forward to meeting with colleagues and experts at the SITC congress and sharing the positive results gained with the MVdeltaC vaccine," said Jean-François Le Bigot, CEO of Oncovita, and Frédéric Tangy, CSO. "Our goal is now to move MVdeltaC to clinical trials, alone or in addition to ICIs, and to provide new treatment options for cancer patients."

All accepted abstracts will be available in a [Journal for Immunotherapy of Cancer \(JITC\)](#) supplement, which will be published on November 7, at 8 a.m. (EST) The supplement will also be available on the [SITC website](#).

#### **About Oncovita**

Oncovita, a spin-off of the Institut Pasteur, is a biotech company dedicated to the development of new life-saving treatments and vaccines, in particular anti-cancer therapies. Oncovita is developing a pipeline of candidates based on a disruptive technology and its proprietary platform Measovir™. The technology engineers selected changes in the measles viral genome designed to dramatically increase its anti-tumor properties. This plug-and-play platform allows production of candidates with high immunogenic apoptotic activities. The mission is to develop these candidates from preclinical to clinical proof-of-concept.



For further information: [contact@oncovita.fr](mailto:contact@oncovita.fr) and [www.oncovita.fr](http://www.oncovita.fr)

---

Media and analyst contact  
**Andrew Lloyd & Associates**  
Celine Gonzalez / Saffiyah Khaliq  
[celine@ala.com](mailto:celine@ala.com) / [saffiyah@ala.com](mailto:saffiyah@ala.com)  
UK: +44 1273 952 481  
US: + 1 617 202 4491  
@ALA\_Group

---